Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.006 0.65% 0.936 0.936 0.938 0.938 0.928 0.93 1,762,392 16:35:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 99.5 79.7 5.8 16.1 1,286

Biopharma Credit Share Discussion Threads

Showing 101 to 124 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
14/9/2022
08:24
And the results are well on track: https://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/half-yearly-report/202209140700103538Z/
jonwig
14/9/2022
08:05
They've scored again, $16m in prepayment fees: https://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/statement-re-sarepta-therapeutics--inc./202209140700103539Z/
jonwig
22/8/2022
17:07
RNS: Pharmakon Advisors, the Investment Manager of BioPharma Credit plc (the "Company") notes the announcement released on Friday 13 August 2022 by Ipsen ("IPN") regarding the completion of its acquisition of Epizyme Inc ("Epizyme") (the "Transaction"). The Company had a US$110 million investment in a senior secured loan to Epizyme which was prepaid upon the closing of the Transaction. The loan was made in four different tranches and each tranche had different prepayment economics. The Company received US$119 million including US$9 million in prepayment and make-whole fees realizing an IRR of 15.2 per cent.
jonwig
18/8/2022
08:02
hTTps://quoteddata.com/2022/08/quoteddatas-weekly-news-show-12th-august-2022/?
davebowler
09/8/2022
12:54
Dollar has done so much for me this year
williamcooper104
09/8/2022
10:50
I have certainly enjoyed my dollar distributions.
hpcg
09/8/2022
09:18
Been a good stock this year though that was driven fully by strong USD. Very illiquid.
smidge21
09/8/2022
09:16
Suggests GBT using things like this to deter acquirors
smidge21
09/8/2022
07:13
$38mn on an investment of $132.5mn seems a huge amount to me. They've had this sort of thing before: loans with high interest and strong early payment covenants. Not that I'm complaining.
jonwig
09/8/2022
07:07
Pharmakon Advisors, the Investment Manager of BioPharma Credit PLC (the "Company") notes the announcement released yesterday by Pfizer Inc. ("Pfizer") regarding the definitive agreement pursuant to which Pfizer will acquire Global Blood Therapeutics Inc. ("GBT") (the "Transaction"). The Company has a US$132.5 million investment in a senior secured loan to GBT which would be prepaid upon the closing of the Transaction. The loan was invested in three different tranches with each tranche subject to different prepayment economics. Assuming the prepayment occurs on 1 October 2022, the Company would be expected to receive approximately US$38 million in paydown, prepayment and make-whole fees.
smidge21
08/8/2022
13:11
Https://www.businesswire.com/news/home/20220808005250/en/ Press release announcing that Pfizer and Global Blood Therapeutics have entered into a definitive agreement for Pfizer to acquire GBT.
gsbmba99
27/7/2022
10:50
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/88646139 As at the 30 June 2022 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.72 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [30/6/22: 100.72 cents per share] [31/5/22: 99.81 cents per share] [30/4/22: 100.83 cents per share] [31/3/22: 100.11 cents per share] [28/2/22: 101.03 cents per share] [31/1/22: 100.07 cents per share] [31/12/21: 99.26 cents per share] [30/11/21: 98.94 cents per share] [31/10/21: 100.23 cents per share] [30/9/21: 99.62 cents per share] [31/8/21: 99.22 cents per share] [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
speedsgh
20/7/2022
15:49
I did notice that, not sure what it means. If they were struggling to be a going concern they probably wouldn't be paying down debt early and BPCR wouldn't be expecting the remaining debt to be payed off as per the original agreement. Access to capital is tight everywhere but especially in this sector at the moment. Hopefully someone with an idea of the implications or more of a clue than me looks in on this thread from time to time.
pjmurf
20/7/2022
12:50
Yes, a strong reaction. But when I read the Akebia RNS, I was puzzled by this: ... waive the requirement that the Company's Quarterly Reports on Form 10-Q for the fiscal quarters ending 30 June 2022 and 30 September 2022 not be subject to any qualification as to going concern, I wasn't at all sure what the implications were!
jonwig
20/7/2022
12:09
More capital returned today hopefully they can find somewhere to reinvest it quickly rather than share buybacks.
pjmurf
28/6/2022
14:35
Good interview from last fri, manager quite upbeat: hTTps://quoteddata.com/events/quoteddatas-investment-trust-weekly-news-roundup-show-pedro-gonzalez-de-cosio-biopharma-credit/
rambutan2
28/6/2022
10:54
Plus getting capital back when can likely be reinvested at higher rates in current environment
williamcooper104
28/6/2022
09:04
I'm pretty happy with that actually, though most of the words I could write have been so already by Liberum. I think there are likely to be incrementally better terms to be written now and cash provides a lot of optionality.
hpcg
28/6/2022
08:56
Liberum; Small NAV gain expected after Epizyme takeover Mkt Cap £1,053m | Share price $0.94 | Prem/(disc) -5.8% | Div yield 7.4% Event Ipsen has agreed to acquire Epizyme, one of the borrower's in BPCR's portfolio (representing 7.4% of total investments). The transaction is expected to close in Q3 2022. The main focus of the acquisition is Tazverik, a small molecule drug for the treatment of several cancer types. The drug was granted accelerated approval by the US FDA in 2020. Epizyme is a biopharmaceutical company focused on cancer and other diseases through novel epigenetic medicines. Biopharma Credit has a $110m outstanding loan to Epizyme. The total facility to Epizyme is $220m, with the remainder funded by Biopharma Credit Investments V. Depending on the time of the prepayment, BPCR expects to receive between $3m-$7m in prepayment and make-whole fees. Liberum view BPCR's loans are typically structured to provide protection against cash drag from repayments in the form of prepayment fees and make-whole penalties. At 31 May 2022, BPCR had cash of $12m and $138m drawn under its credit facilities. We expect robust performance as 58% of the portfolio benefits from floating rate coupons. LIBOR floors on these loans range from 1-2% and further uplifts in LIBOR from current levels will deliver incremental improvements in returns. The prepayment penalties on the Epizyme loan will add between 0.2%-0.5% to NAV. We note recent weakness in the share price and believe the shares offer considerable downside protection at these levels. The company has a discount control mechanism in place if the discount trades at an average discount in excess of 5% in any three-month rolling period.
davebowler
28/6/2022
07:07
Could be better than that. Here's BPCR's statement today: Pharmakon Advisors, the Investment Manager of BioPharma Credit PLC (the "Company") notes the announcement released yesterday by Ipsen ("IPN") regarding the definitive agreement pursuant to which Ipsen will acquire Epizyme Inc ("Epizyme") (the "Transaction"). The Company has a US$110 million investment in a senior secured loan to Epizyme which would be prepaid upon the closing of the Transaction. The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the Company would be expected to receive between US$3 to US$7 million in prepayment and make-whole fees. https://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/statement-re-epizyme/202206280700043676Q/
jonwig
27/6/2022
13:35
Ipsen offer for Epizyme where BPCR has lent $110m at L+7.75% (2% LIBOR floor) due November 2025 (and Royalty Pharma has a shareholding). Looks like a pre-payment fee of 2% if repaid before November 18 2022 (1% if before November 2023).
gsbmba99
05/4/2022
09:11
hTTps://www.edisongroup.com/publication/new-transaction-of-up-to-us50m/30623/
davebowler
22/3/2022
08:27
Just a shame we don't have a more granular loan book here It's what's always held me of from buying more here
williamcooper104
22/3/2022
08:25
I'm always surprised at the high interest rates these biopharma companies are willing and able to borrow at. On top of that, the loans are usually amortising and have upfront early repayment charges.
jonwig
Chat Pages: 5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
BPCR
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221004 04:45:40